$NRIX
Nurix Therapeutics, Inc.

2025 Q1 Form 10-K Financial Statement

#000154959525000016 Filed on January 28, 2025

View on sec.gov

Income Statement

Concept 2025 Q1 2024 Q4 2024
Revenue $54.55M
YoY Change -29.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $221.6M
YoY Change 17.17%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $267.6M
YoY Change 15.31%
Operating Profit -$213.0M
YoY Change 37.38%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$193.3M
YoY Change 34.28%
Income Tax $270.0K
% Of Pretax Income
Net Earnings -$193.6M
YoY Change 34.47%
Net Earnings / Revenue -354.85%
Basic Earnings Per Share -$2.88
Diluted Earnings Per Share -$2.88
COMMON SHARES
Basic Shares Outstanding 75.89M shares 70.84M shares 67.12M shares
Diluted Shares Outstanding 67.12M shares

Balance Sheet

Concept 2025 Q1 2024 Q4 2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $110.0M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $619.4M
YoY Change 109.6%
LONG-TERM ASSETS
Property, Plant & Equipment $17.76M
YoY Change 5.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.159M
YoY Change -17.37%
Total Long-Term Assets $49.96M
YoY Change -16.87%
TOTAL ASSETS
Total Short-Term Assets $619.4M
Total Long-Term Assets $49.96M
Total Assets $669.3M
YoY Change 88.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.48M
YoY Change 79.38%
Accrued Expenses
YoY Change
Deferred Revenue $38.36M
YoY Change -20.24%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $95.85M
YoY Change 10.23%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $95.85M
Total Long-Term Liabilities
Total Liabilities $142.4M
YoY Change -8.22%
SHAREHOLDERS EQUITY
Retained Earnings -$738.8M
YoY Change 35.51%
Common Stock $1.266B
YoY Change 69.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $527.0M
YoY Change
Total Liabilities & Shareholders Equity $669.3M
YoY Change 88.23%

Cashflow Statement

Concept 2025 Q1 2024 Q4 2024
OPERATING ACTIVITIES
Net Income -$193.6M
YoY Change 34.47%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$172.6M
YoY Change 112.11%
INVESTING ACTIVITIES
Capital Expenditures $9.273M
YoY Change 10.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$257.7M
YoY Change -477.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $289.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $485.7M
YoY Change 14996.89%
NET CHANGE
Cash From Operating Activities -$172.6M
Cash From Investing Activities -$257.7M
Cash From Financing Activities $485.7M
Net Change In Cash $55.37M
YoY Change -662.3%
FREE CASH FLOW
Cash From Operating Activities -$172.6M
Capital Expenditures $9.273M
Free Cash Flow -$181.9M
YoY Change 102.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-11-30
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024 dei City Area Code
CityAreaCode
415
CY2024 dei Local Phone Number
LocalPhoneNumber
660-5320
CY2024 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024 dei Trading Symbol
TradingSymbol
NRIX
CY2024 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2024 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2024 dei Entity Small Business
EntitySmallBusiness
false
CY2024 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 cyd Cybersecurity Risk Management Processes Integrated Flag
CybersecurityRiskManagementProcessesIntegratedFlag
true
CY2024 cyd Cybersecurity Risk Third Party Oversight And Identification Processes Flag
CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
true
CY2024 cyd Cybersecurity Risk Management Third Party Engaged Flag
CybersecurityRiskManagementThirdPartyEngagedFlag
true
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2024 cyd Cybersecurity Risk Management Positions Or Committees Responsible Flag
CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
true
CY2024 cyd Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag
CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
true
CY2024 cyd Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag
CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
false
CY2024 dei Auditor Firm
AuditorFirmId
238
CY2024 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2024 dei Auditor Location
AuditorLocation
San Jose, California
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109997000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54627000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
499586000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
233281000 usd
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9804000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7595000 usd
CY2024Q4 us-gaap Assets Current
AssetsCurrent
619387000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
295503000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
7421000 usd
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28139000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31142000 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17757000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16808000 usd
CY2024Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2024Q4 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2024Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3159000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3823000 usd
CY2024Q4 us-gaap Assets
Assets
669343000 usd
CY2023Q4 us-gaap Assets
Assets
355598000 usd
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11482000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6401000 usd
CY2024Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
37994000 usd
CY2023Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
24970000 usd
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8014000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7489000 usd
CY2024Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
38364000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
48098000 usd
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95854000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86958000 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20289000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23125000 usd
CY2024Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26207000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45022000 usd
CY2024Q4 us-gaap Liabilities
Liabilities
142350000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
155105000 usd
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
95854000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86958000 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20289000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23125000 usd
CY2024Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
26207000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45022000 usd
CY2024Q4 us-gaap Liabilities
Liabilities
142350000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
155105000 usd
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75870718 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75870718 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48718552 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48718552 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
76000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49000 usd
CY2024Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1265536000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
746299000 usd
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-655000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-738769000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-545200000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
526993000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
200493000 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
669343000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355598000 usd
CY2024 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54549000 usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76987000 usd
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
221632000 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
189148000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
184497000 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45944000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42902000 usd
CY2024Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75870718 shares
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75870718 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48718552 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48718552 shares
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
76000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
49000 usd
CY2024Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1265536000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
746299000 usd
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-655000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-738769000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-545200000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
526993000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
200493000 usd
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
669343000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355598000 usd
CY2024 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54549000 usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76987000 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38627000 usd
CY2024 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
221632000 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
189148000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
184497000 usd
CY2024 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45944000 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42902000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37997000 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
267576000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
232050000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
222494000 usd
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-213027000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-155063000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-183867000 usd
CY2024 us-gaap Interest And Other Income
InterestAndOtherIncome
19728000 usd
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
11115000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37997000 usd
CY2024 us-gaap Operating Expenses
OperatingExpenses
267576000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
232050000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
222494000 usd
CY2024 us-gaap Operating Income Loss
OperatingIncomeLoss
-213027000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-155063000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-183867000 usd
CY2024 us-gaap Interest And Other Income
InterestAndOtherIncome
19728000 usd
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
11115000 usd
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
3507000 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-193299000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-143948000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-180360000 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
270000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.71
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67120266 shares
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67120266 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54337901 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54337901 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48607990 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48607990 shares
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2024 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
805000 usd
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3664000 usd
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3711000 usd
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-192764000 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-140284000 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-184071000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
94759000 usd
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1955000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28200000 usd
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3711000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2023 nrix Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
717360 shares
CY2023 nrix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2000 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
986000 usd
CY2023 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
117000 usd
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2229000 usd
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
3507000 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-193299000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-143948000 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
270000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.71
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67120266 shares
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67120266 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54337901 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54337901 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48607990 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48607990 shares
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2024 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
805000 usd
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3664000 usd
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3711000 usd
CY2024 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-192764000 usd
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-140284000 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-184071000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
94759000 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1078000 usd
CY2022 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
145000 usd
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1955000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28200000 usd
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3711000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2023 nrix Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
717360 shares
CY2023 nrix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2000 usd
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
986000 usd
CY2023 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
117000 usd
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2229000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33747000 usd
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3664000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
200493000 usd
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188732000 usd
CY2024 nrix Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
19750 shares
CY2024 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5055000 usd
CY2024 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
33000 usd
CY2024 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2132000 usd
CY2024 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33943000 usd
CY2024 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
805000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
526993000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2024 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9318000 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7533000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5349000 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
33929000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
33673000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
28131000 usd
CY2024 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11288000 usd
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5421000 usd
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-426000 usd
CY2024 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-31000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5459000 usd
CY2024 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-286000 usd
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-201000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33747000 usd
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3664000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
200493000 usd
CY2024 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188732000 usd
CY2024 nrix Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
19750 shares
CY2024 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5055000 usd
CY2024 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33943000 usd
CY2024 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
805000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
526993000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2024 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9318000 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7533000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5349000 usd
CY2024 us-gaap Share Based Compensation
ShareBasedCompensation
33929000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
33673000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
28131000 usd
CY2024 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11288000 usd
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5421000 usd
CY2024 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-31000 usd
CY2024 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
7110000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5459000 usd
CY2024 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-286000 usd
CY2023 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-201000 usd
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6000000 usd
CY2024 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
459000 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2139000 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1094000 usd
CY2024 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5209000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1614000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
85000 usd
CY2024 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28549000 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
19513000 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-26627000 usd
CY2024 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6418000 usd
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6268000 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4871000 usd
CY2024 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11816000 usd
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3123000 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7485000 usd
CY2024 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6000000 usd
CY2024 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
459000 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2139000 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1094000 usd
CY2024 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5209000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1614000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
85000 usd
CY2024 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28549000 usd
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
19513000 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-26627000 usd
CY2024 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6418000 usd
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-6268000 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4871000 usd
CY2024 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11816000 usd
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
3123000 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7485000 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172584000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81365000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159807000 usd
CY2024 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
707953000 usd
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
246334000 usd
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
239366000 usd
CY2024 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
459513000 usd
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
323036000 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
278808000 usd
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9273000 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8401000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12244000 usd
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-257713000 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
68301000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27198000 usd
CY2024 nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
188732000 usd
CY2023 nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
CY2022 nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
94759000 usd
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
289763000 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19400000 usd
CY2024 nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
5055000 usd
CY2023 nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
988000 usd
CY2022 nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
1078000 usd
CY2024 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2132000 usd
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2229000 usd
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1955000 usd
CY2024 nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
15000 usd
CY2023 nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
0 usd
CY2022 nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
0 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
485667000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3217000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117192000 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55370000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9847000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15417000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55528000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110898000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55528000 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-172584000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-81365000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159807000 usd
CY2024 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
707953000 usd
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
246334000 usd
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
239366000 usd
CY2024 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
459513000 usd
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
323036000 usd
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
278808000 usd
CY2024 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9273000 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8401000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12244000 usd
CY2024 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-257713000 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
68301000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27198000 usd
CY2024 nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
188732000 usd
CY2023 nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
CY2022 nrix Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
94759000 usd
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
289763000 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2024 nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
5055000 usd
CY2023 nrix Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
988000 usd
CY2024 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2132000 usd
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2229000 usd
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1955000 usd
CY2024 nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
15000 usd
CY2023 nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
0 usd
CY2022 nrix Payments For Repurchase Of Stock Options
PaymentsForRepurchaseOfStockOptions
0 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
485667000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3217000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117192000 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55370000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9847000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15417000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55528000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110898000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55528000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2024 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1643000 usd
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
632000 usd
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1373000 usd
CY2024Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
100000 usd
CY2024Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
100000 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
500000 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
500000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2024 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1643000 usd
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1373000 usd
CY2024 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4107000 usd
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23995000 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5068000 usd
CY2024 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
14000 usd
CY2022 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
69000 usd
CY2024 nrix Deferred Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities
117000 usd
CY2023 nrix Deferred Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities
0 usd
CY2022 nrix Deferred Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities
0 usd
CY2024 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
394000 usd
CY2023 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
0 usd
CY2024 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4107000 usd
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23995000 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5068000 usd
CY2024 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
14000 usd
CY2023 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
74000 usd
CY2022 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
69000 usd
CY2024 nrix Deferred Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities
117000 usd
CY2023 nrix Deferred Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities
0 usd
CY2022 nrix Deferred Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities
DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities
0 usd
CY2024 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
394000 usd
CY2023 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
0 usd
CY2022 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
72000 usd
CY2024 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
33000 usd
CY2022 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
145000 usd
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109997000 usd
CY2022 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
72000 usd
CY2022 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
145000 usd
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109997000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54627000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64474000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110898000 usd
CY2024Q4 nrix Working Capital
WorkingCapital
523500000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-738800000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54627000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64474000 usd
CY2024Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110898000 usd
CY2024Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
609600000 usd
CY2024Q4 nrix Working Capital
WorkingCapital
523500000 usd
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-738800000 usd
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company also makes certain commencement date estimates for its leases, including the incremental borrowing rate, the expected lease term and the fair value of the leased asset. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.</span></div>
CY2024 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s marketable securities consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</span></div>
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2024 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2024 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2024Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2024Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2019Q2 nrix Number Of Drug Candidates
NumberOfDrugCandidates
1 candidate
CY2024Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52259000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43057000 usd
CY2024Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34502000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26249000 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17757000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16808000 usd
CY2024 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9300000 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7500000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5300000 usd
CY2019Q2 nrix Number Of Drug Candidates
NumberOfDrugCandidates
1 candidate
CY2024Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52259000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
43057000 usd
CY2024Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
34502000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26249000 usd
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17757000 usd
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7500000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5300000 usd
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16631000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15303000 usd
CY2024Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
11599000 usd
CY2023Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
3767000 usd
CY2024Q4 nrix Accrued Clinical Current
AccruedClinicalCurrent
4637000 usd
CY2023Q4 nrix Accrued Clinical Current
AccruedClinicalCurrent
3364000 usd
CY2024Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1615000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1755000 usd
CY2024Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1237000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
30000 usd
CY2024Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2275000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
751000 usd
CY2024Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
37994000 usd
CY2023Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
24970000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
166161000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
138000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
3981000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
15000 usd
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16631000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15303000 usd
CY2024Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
11599000 usd
CY2023Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
3767000 usd
CY2024Q4 nrix Accrued Clinical Current
AccruedClinicalCurrent
4637000 usd
CY2023Q4 nrix Accrued Clinical Current
AccruedClinicalCurrent
3364000 usd
CY2024Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1615000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1755000 usd
CY2024Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1237000 usd
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
30000 usd
CY2024Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2275000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
751000 usd
CY2024Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
37994000 usd
CY2023Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
24970000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
166161000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
138000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
3981000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
15000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
170142000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
153000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
70293000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
112000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
58172000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
609000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
721000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2024Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0 usd
CY2023Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2023 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2024 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2022 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2024Q4 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
57902 sqft
CY2024Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2024Q3 nrix Operating Lease Rent Payable Adjustment Per Month
OperatingLeaseRentPayableAdjustmentPerMonth
400000 usd
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320 sqft
CY2024Q1 nrix Operating Lease Rent Payable Adjustment Per Month
OperatingLeaseRentPayableAdjustmentPerMonth
100000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
170142000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
153000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
70293000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
112000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
58172000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
609000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
128465000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
721000 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2024Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0 usd
CY2023Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2024Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 position
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2024Q4 us-gaap Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest
DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
0 usd
CY2023 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2024 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2022 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0 usd
CY2024Q4 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
57902 sqft
CY2024Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2024Q3 nrix Operating Lease Rent Payable Adjustment Per Month
OperatingLeaseRentPayableAdjustmentPerMonth
400000 usd
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320 sqft
CY2022Q1 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
46434 sqft
CY2023Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
50094 sqft
CY2022Q1 nrix Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 option
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024 us-gaap Variable Lease Payment
VariableLeasePayment
7000000.0 usd
CY2022Q1 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
46434 sqft
CY2022Q1 nrix Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 option
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024 us-gaap Variable Lease Payment
VariableLeasePayment
7000000.0 usd
CY2023 us-gaap Variable Lease Payment
VariableLeasePayment
6200000 usd
CY2022 us-gaap Variable Lease Payment
VariableLeasePayment
4400000 usd
CY2024 us-gaap Operating Lease Expense
OperatingLeaseExpense
9000000.0 usd
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
6800000 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
5900000 usd
CY2024Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2024Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0684
CY2024 us-gaap Operating Lease Payments
OperatingLeasePayments
8320000 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
6973000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6578000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8240000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2912000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2992000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3074000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
18073000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38450000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10147000 usd
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
28303000 usd
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8014000 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20289000 usd
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
28303000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024 nrix Common Stock Voting Rights For Shareholders
CommonStockVotingRightsForShareholders
1 vote
CY2024 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023 us-gaap Variable Lease Payment
VariableLeasePayment
6200000 usd
CY2022 us-gaap Variable Lease Payment
VariableLeasePayment
4400000 usd
CY2024 us-gaap Operating Lease Expense
OperatingLeaseExpense
9000000.0 usd
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
6800000 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
5900000 usd
CY2024Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2024Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0684
CY2024 us-gaap Operating Lease Payments
OperatingLeasePayments
8320000 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
6973000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6578000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8240000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2912000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2992000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3074000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3159000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
18073000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
38450000 usd
CY2024Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10147000 usd
CY2024Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
28303000 usd
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8014000 usd
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20289000 usd
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024 nrix Common Stock Voting Rights For Shareholders
CommonStockVotingRightsForShareholders
1 vote
CY2024 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2024Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24307177 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18828875 shares
CY2024Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24307177 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18828875 shares
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5600000 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4500000 usd
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.96
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.80
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5600000 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 usd
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.96
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.80
CY2024Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
52800000 usd
CY2024 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M19D
CY2024Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
52800000 usd
CY2024 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M19D
CY2024 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000 usd
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000.0 usd
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
270000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-193299000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-143948000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-180360000 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-193299000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-143948000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-180360000 usd
CY2024 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
270000 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2024 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2024 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
270000 usd
CY2024 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000 usd
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000.0 usd
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
270000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-193299000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-143948000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-180360000 usd
CY2024 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-193299000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-143948000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-180360000 usd
CY2024 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
270000 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2024 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2024 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
270000 usd
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.049
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.141
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.041
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.048
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.035
CY2024 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.015
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.042
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.020
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.186
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.356
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.284
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 usd
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 usd
CY2024 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2024 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.049
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.141
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2024 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.041
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.048
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.035
CY2024 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.015
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.042
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.020
CY2024 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.186
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.356
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.284
CY2024 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2024 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
91786000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
92131000 usd
CY2024Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
48307000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
37052000 usd
CY2024Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12683000 usd
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11143000 usd
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5310000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5472000 usd
CY2024Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
3199000 usd
CY2023Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
3723000 usd
CY2024Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
6125000 usd
CY2023Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
8789000 usd
CY2024Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
65729000 usd
CY2023Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
44348000 usd
CY2024Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
233139000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
202658000 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
227050000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193717000 usd
CY2024Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6089000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8941000 usd
CY2024Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
6089000 usd
CY2023Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
8941000 usd
CY2024Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6089000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8941000 usd
CY2024Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
33300000 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
227100000 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
55400000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193700000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21900000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 usd
CY2024Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
91786000 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
92131000 usd
CY2024Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
48307000 usd
CY2024Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
12683000 usd
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11143000 usd
CY2024Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5310000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5472000 usd
CY2024Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
3199000 usd
CY2023Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
3723000 usd
CY2024Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
6125000 usd
CY2023Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
8789000 usd
CY2024Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
65729000 usd
CY2023Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
44348000 usd
CY2024Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
233139000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
202658000 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
227050000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193717000 usd
CY2024Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
6089000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8941000 usd
CY2024Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
6089000 usd
CY2023Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
8941000 usd
CY2024Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6089000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8941000 usd
CY2024Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2024 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
33300000 usd
CY2024Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
227100000 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
55400000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
193700000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21900000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15508000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10261000 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6331000 usd
CY2024 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6358000 usd
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
5247000 usd
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3930000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21866000 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15508000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10261000 usd
CY2024Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
65700000 usd
CY2023Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
44300000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67120266 shares
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67120266 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54337901 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54337901 shares
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15508000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10261000 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6331000 usd
CY2024 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6358000 usd
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
5247000 usd
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3930000 usd
CY2024Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
21866000 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15508000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10261000 usd
CY2024Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
65700000 usd
CY2023Q4 nrix Deferred Tax Assets Capitalized Research And Experimental Expenses
DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses
44300000 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67120266 shares
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67120266 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54337901 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54337901 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48607990 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48607990 shares
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.71
CY2024 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11867010 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48607990 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48607990 shares
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9795222 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9187221 shares
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024 ecd Insider Trd Policies Proc Adopted Flag
InsiderTrdPoliciesProcAdoptedFlag
true
CY2024 ecd Insider Trd Policies Proc Adopted Flag
InsiderTrdPoliciesProcAdoptedFlag
true
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9795222 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9187221 shares
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024 ecd Insider Trd Policies Proc Adopted Flag
InsiderTrdPoliciesProcAdoptedFlag
true
CY2024 ecd Insider Trd Policies Proc Adopted Flag
InsiderTrdPoliciesProcAdoptedFlag
true
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-193569000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-143948000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2023 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
117000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55528000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001549595
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Amendment Flag
AmendmentFlag
false
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
001-39398
CY2024 dei Entity Registrant Name
EntityRegistrantName
NURIX THERAPEUTICS, INC.
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0838048
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
1700 Owens Street
CY2024 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2024 dei Entity Shell Company
EntityShellCompany
false
CY2024 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2024Q2 dei Entity Public Float
EntityPublicFloat
995900000 usd
CY2025Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75886817 shares
CY2024 dei Document Type
DocumentType
10-K
CY2023 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-556000 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9000 usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6121000 usd

Files In Submission

Name View Source Status
0001549595-25-000016-index-headers.html Edgar Link pending
0001549595-25-000016-index.html Edgar Link pending
0001549595-25-000016.txt Edgar Link pending
0001549595-25-000016-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-20241130.htm Edgar Link pending
nrix-20241130.xsd Edgar Link pending
nrix-20241130xex191insider.htm Edgar Link pending
nrix-20241130xex231consent.htm Edgar Link pending
nrix-20241130xex311.htm Edgar Link pending
nrix-20241130xex312.htm Edgar Link pending
nrix-20241130xex321.htm Edgar Link pending
nrix-20241130_g1.jpg Edgar Link pending
nrix-20241130_g10.jpg Edgar Link pending
nrix-20241130_g11.jpg Edgar Link pending
nrix-20241130_g12.jpg Edgar Link pending
nrix-20241130_g13.jpg Edgar Link pending
nrix-20241130_g14.jpg Edgar Link pending
nrix-20241130_g15.jpg Edgar Link pending
nrix-20241130_g16.jpg Edgar Link pending
nrix-20241130_g17.jpg Edgar Link pending
nrix-20241130_g18.jpg Edgar Link pending
nrix-20241130_g19.jpg Edgar Link pending
nrix-20241130_g2.jpg Edgar Link pending
nrix-20241130_g20.jpg Edgar Link pending
nrix-20241130_g21.jpg Edgar Link pending
nrix-20241130_g22.jpg Edgar Link pending
nrix-20241130_g23.jpg Edgar Link pending
nrix-20241130_g3.jpg Edgar Link pending
nrix-20241130_g4.jpg Edgar Link pending
nrix-20241130_g5.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrix-20241130_cal.xml Edgar Link unprocessable
nrix-20241130_def.xml Edgar Link unprocessable
nrix-20241130_g6.jpg Edgar Link pending
nrix-20241130_g7.jpg Edgar Link pending
nrix-20241130_g8.jpg Edgar Link pending
nrix-20241130_g9.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
nrix-20241130_pre.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nrix-20241130_lab.xml Edgar Link unprocessable
nrix-20241130_htm.xml Edgar Link completed